The research team, drawn from institutions including Kastamonu University and Karabuk University, set out to fill a gap in the sports nutrition literature. Caffeine is arguably the best-studied ergogenic aid on the planet, working largely by blocking adenosine receptors in the brain, which blunts the perception of fatigue and sharpens alertness and motor control. Rhodiola rosea, by contrast, is an adaptogen — a plant extract traditionally used to improve resilience to physical and mental stress — with proposed anti-fatigue and anti-hypoxic properties. Despite decades of separate research on each, direct comparisons of the two, and of their combination, under controlled laboratory conditions have been scarce, particularly in soccer players whose sport demands repeated explosive sprints.

The experimental design was a single-blind, randomized, four-condition crossover. Each participant completed every condition in a randomized order separated by 72-hour washout periods: a cellulose placebo, caffeine at 3 milligrams per kilogram of body weight, standardized Rhodiola rosea extract at the same 3 milligrams per kilogram dose, and the two together. The Rhodiola product was a commercial standardized extract supplying salidroside and rosavins, the compounds most often credited with the herb’s adaptogenic activity. Sixty minutes after swallowing the capsules, the players performed a Wingate anaerobic test on a mechanically braked cycle ergometer, with resistance set at 7.5 percent of body mass — the classic laboratory proxy for the explosive, anaerobic efforts that decide soccer matches.

The performance results centered on the combined condition. Peak power output averaged 867.7 watts after the caffeine-plus-Rhodiola dose, against 755.7 watts after placebo — a difference of roughly 112 watts that reached statistical significance. Relative to body mass, the combined condition produced about 12.12 watts per kilogram versus 10.91 on placebo. Average power, a measure of anaerobic capacity sustained across the full 30 seconds, was also highest after the combined dose, and significantly exceeded the Rhodiola-only condition by about 50 watts. Notably, caffeine alone and Rhodiola alone did not significantly beat placebo on any power metric, which makes the pattern — apparent benefit only when the two are paired — the most intriguing finding of the study.

Alongside the ergometer data, the researchers collected saliva immediately after each test and measured three biomarkers using enzyme-linked immunosorbent assays: cortisol, the body’s principal stress hormone; alpha-amylase, a marker of sympathetic nervous system activation; and secretory immunoglobulin A, a first-line antibody of the mucosal immune system. Cortisol concentrations were significantly higher in the combined condition than after placebo. Alpha-amylase, counterintuitively, was significantly lower after caffeine alone than after placebo. And IgA was significantly elevated after Rhodiola alone, a result the authors flag as relevant to athletes, since falling IgA during heavy training has been linked to increased susceptibility to upper respiratory infections.

The authors are careful — unusually so for this field — about what these numbers do and do not prove. Because the study used repeated-measures ANOVA with pairwise comparisons rather than a formal interaction analysis, the superior results in the combined arm cannot be statistically attributed to a true synergistic interaction between caffeine and Rhodiola. The paper repeatedly stresses that the findings represent condition-specific acute responses that require confirmation in larger, better-powered trials. The researchers also note that the biomarkers were sampled within roughly a minute after the Wingate test, capturing only an early snapshot of the neuroendocrine stress response rather than its peak, and that no baseline saliva samples were taken before supplementation in each session.

The limitations section is candid and extensive. With only ten participants, even a crossover design leaves little room for detecting small effects, and the a priori power calculation assumed a relatively large effect size that was not derived from any single prior study. Habitual caffeine intake was never quantified, so individual tolerance — a known modifier of caffeine’s ergogenic effects — could not be accounted for. Period and sequence effects were not modeled statistically. Salivary flow rate was not measured, meaning IgA was analyzed as a raw concentration rather than a secretion rate. And the sample was exclusively male, limiting generalizability to the growing population of female athletes.

One limitation stands out for its potential to explain the headline result: blinding. The placebo, caffeine, and Rhodiola conditions each involved a single capsule, while the combined condition required two. Participants may well have guessed when they had received the double dose — and the combined condition was precisely the one where positive findings emerged. The authors acknowledge that expectancy effects cannot be excluded and recommend a double-dummy design, in which every condition involves the same number of capsules, along with formal checks of blinding success in future work.

Mechanistically, the researchers offer a plausible but unproven rationale for why the pairing might help. Caffeine’s adenosine blockade could enhance central nervous system drive and neuromuscular recruitment during maximal effort, while Rhodiola’s proposed effects on cellular energy metabolism and stress regulation — possibly involving the hypothalamic–pituitary–adrenal axis — might complement that stimulation. The elevated cortisol seen after the combined dose, they caution, should not be read as a harmful stress response; transient cortisol spikes are part of the normal physiology of intense exercise, and the study captured only one early time point. The lower alpha-amylase after caffeine alone is similarly hard to interpret, since sympathetic activity was not directly measured and prior studies of caffeine’s effects on this marker have been inconsistent.

For now, the practical takeaway is modest. The study offers preliminary evidence that a single acute dose of caffeine plus Rhodiola rosea can raise peak anaerobic power in trained soccer players under laboratory conditions, while leaving open whether that advantage survives on the pitch, in women, or with chronic use. The authors call for larger randomized trials with both sexes, sport-specific performance measures, baseline biomarker sampling, and proper interaction statistics before any definitive recommendations can be made. Until then, the combination remains an intriguing hypothesis rather than a proven recipe — one that the growing market for adaptogenic supplements will no doubt watch closely.

Subject of Research: Acute effects of caffeine and Rhodiola rosea supplementation, alone and combined, on anaerobic performance and salivary stress biomarkers in soccer players

Article Title: Effects of Rhodiola rosea and caffeine, alone and in combination, on Wingate performance and physiological stress responses in soccer players

Article References: Yelken, M. E., Hepsert, S., Küçüksayan, H., Vural, E., Gülten, S., Bildirici, M. A., & Akçay, N. (2026). Effects of Rhodiola rosea and caffeine, alone and in combination, on Wingate performance and physiological stress responses in soccer players. Frontiers in Physiology, 17, Article 1964904. https://doi.org/10.3389/fphys.2026.1964904

Image Credits: AI Generated

DOI: 10.3389/fphys.2026.1964904

Keywords: caffeine, Rhodiola rosea, Wingate anaerobic test, soccer players, ergogenic aids, cortisol, alpha-amylase, immunoglobulin A, crossover trial, exercise physiology, sports nutrition, adaptogens

Allulose, sometimes labeled D-allulose or D-psicose, is a rare sugar that occurs naturally in small quantities in foods such as figs, raisins, and jackfruit. Chemically, it is a C-3 epimer of fructose, meaning it shares fructose’s molecular formula but differs in the spatial orientation of a single hydroxyl group. That tiny structural difference has large metabolic consequences: allulose is poorly digested in the small intestine, contributes negligible calories, and does not meaningfully raise blood glucose or insulin. It has attracted growing attention as a bulk sweetener for sugar-reduced beverages and foods, and recent work has explored how gut microbes can even utilize it as a substrate. Yet while its glycemic profile is well documented, rigorous human evidence that allulose can actively improve rehydration, rather than simply avoid harming it, has been scarce.

The new study, led by Hye Rim Kim and Jinsoo Noh of Samyang Corporation together with colleagues at Yonsei University in South Korea, set out to fill that gap with a carefully controlled human trial. Fifteen healthy men completed the protocol, which used a randomized, double-blind, crossover design widely regarded as the gold standard for nutrition interventions. In a crossover trial, each participant serves as his own control, experiencing both experimental conditions in randomly assigned order with a washout period in between. This design minimizes the noise created by individual differences in sweat rate, fitness, and baseline hydration, which are substantial in fluid-balance research. Neither the participants nor the investigators knew which beverage was consumed on a given trial day, protecting the results from expectation effects.

The experimental challenge was deliberately physiological. Each participant first underwent exercise-induced dehydration, losing body water through physical exertion in a controlled setting, before consuming one of two electrolyte-matched beverages. The drinks were identical in their electrolyte content, so the only meaningful variable was the sweetener: one contained allulose, while the control beverage was sweetened with sucralose, a non-nutritive sweetener that provides sweetness without any carbohydrate transport activity. By matching electrolytes and holding volume constant, the researchers isolated the specific contribution of allulose to the rehydration process. The team then tracked an extensive panel of outcomes, including plasma volume recovery, fluid retention, thirst ratings, body water composition measured by bioelectrical impedance analysis, urine specific gravity, blood glucose, and body temperature.

The headline result was striking. Plasma volume, the liquid component of blood that supports cardiovascular function and thermoregulation during exercise, recovered far more completely in the allulose condition. Participants who drank the allulose beverage showed a plasma volume recovery of roughly 28 percent relative to their post-exercise deficit, compared with only about 4 percent after the sucralose drink, a difference the authors report as statistically significant at p = 0.0001. Fluid retention told a similar story: the allulose drink allowed the body to hold onto approximately 91.5 percent of the ingested fluid, whereas the sucralose control retained about 80.6 percent, a gap of more than ten percentage points that reached significance at p = 0.0023. In practical terms, the allulose beverage did not just quench thirst; it kept the water inside the body where it could do physiological work.

Subjective thirst followed the objective measurements. Participants reported a significantly greater reduction in thirst after the allulose beverage, with a mean thirst reduction score of 6.47 compared with 4.60 for the control, significant at p = 0.0012. This matters because thirst is a surprisingly poor guide to true rehydration. People often stop drinking once oral sensations fade, long before plasma volume and cellular hydration are fully restored, a phenomenon that contributes to chronic mild dehydration in athletes and ordinary people alike. A beverage that both relieves thirst and measurably improves fluid retention addresses both the behavioral and the physiological sides of the problem. Notably, the researchers found no glycemic cost: blood glucose was not adversely affected, and there was no thermoregulatory penalty, meaning the sugar did not interfere with the body’s temperature control after exercise.

Why would a poorly digested sugar enhance fluid retention at all? The most plausible mechanism, which the authors situate within existing literature, involves sodium-glucose cotransport. The intestinal transporter SGLT1 couples the uptake of glucose and sodium, and in doing so creates an osmotic gradient that pulls water across the gut lining. Research on this transporter has shown it is an extraordinarily efficient facilitator of passive water movement, which is precisely why oral rehydration solutions for illness rely on glucose and sodium in balanced proportions. Although allulose is only partially absorbed, some transport activity appears sufficient to augment water uptake and, critically, to help retain absorbed fluid within the vascular and cellular compartments rather than letting the kidneys excrete it rapidly. The kidney’s own sodium-glucose cotransport systems may also contribute to keeping filtered water in the body.

The study’s measurement strategy adds credibility to these conclusions. Bioelectrical impedance analysis allowed the team to distinguish total body water, extracellular water, and intracellular water, offering a window into where the retained fluid actually resided. Urine specific gravity served as a standard clinical index of hydration status, reflecting how concentrated the kidneys are making urine; a lower value after rehydration indicates the body is conserving water rather than dumping it. Combining these objective markers with plasma volume estimates and subjective thirst scales gives a more complete picture than any single measure could, and the consistency across outcomes strengthens the case that the effect is real rather than a statistical artifact.

Several caveats deserve attention. The sample comprised fifteen healthy men, so the findings cannot yet be generalized to women, older adults, or clinical populations, and the modest sample size, while typical for crossover metabolic studies, means the confidence intervals around the effect estimates are wide. The trial was funded by Samyang Corporation, which provided the study material, and most of the authors are affiliated with the company; the disclosure is transparent, but independent replication will be important before the results are treated as settled. The comparison sweetener, sucralose, was a sensible inert control, but future work comparing allulose directly against glucose-based sports drinks would clarify whether it matches or exceeds the gold standard, not merely whether it beats a non-transported sweetener. Doses, timing, and effects during exercise rather than after it also remain open questions.

Even with those limitations, the implications are compelling. Sports nutrition guidelines have long emphasized that fluid replacement after exercise should account for electrolyte losses and that carbohydrate can aid absorption, but the caloric arithmetic has always been awkward for the vast majority of people who exercise for health rather than performance. Sugar-sweetened beverages are firmly implicated in the global rise of obesity and type 2 diabetes, while purely non-nutritive sweeteners have faced persistent questions about metabolic effects. Allulose occupies a genuinely different position: it tastes and behaves like a sugar in formulation, it is metabolically stable and largely excreted or fermented rather than converted to energy, and this trial now provides human evidence that it can actively enhance plasma volume recovery and fluid retention after dehydration. If larger independent trials confirm these findings, the rehydration aisle could be reshaped by a rare sugar that most consumers have never heard of, one that helps the body hold onto water without holding onto calories.

Subject of Research: Effects of allulose on post-exercise rehydration and plasma volume recovery in humans

Article Title: Allulose enhances plasma volume recovery and fluid retention after exercise-induced dehydration: a randomized, double-blind, crossover trial

Article References: Kim, H. R., Noh, J., Park, J., Hwang, H., Han, J., & Byun, S. (2026). Allulose enhances plasma volume recovery and fluid retention after exercise-induced dehydration: a randomized, double-blind, crossover trial. Food Science and Biotechnology. https://doi.org/10.1007/s10068-026-02329-z

Image Credits: AI Generated

DOI: 10.1007/s10068-026-02329-z

Keywords: allulose, rehydration, dehydration, plasma volume, fluid retention, exercise, rare sugar, sports nutrition, sucralose, crossover trial, sodium-glucose cotransport, low-calorie sweetener

The research team, led by Seung-Bo Park and Junggi Hong of CHA University’s Graduate School of Sports Medicine, recruited 14 adults with type 2 diabetes and asked each of them to complete three separate walking sessions. In one condition, participants walked normally with no robotic assistance. In the other two, they wore the Bot-Fit wearable hip exoskeleton, a Samsung Electronics-developed device that attaches around the hips and thighs and uses motorized assistance or resistance at the hip joints to alter how hard the muscles must work during each stride. The two robotic modes, called Aqua and Boost, were designed to impose different physiological demands.

The experimental design was deliberately rigorous for a proof-of-concept study. Because glucose responses vary widely from person to person and from day to day, the investigators used a randomized, partially counterbalanced crossover protocol, meaning every participant experienced all three walking conditions, with the order shuffled to cancel out carryover effects. Walking intensity was individualized by setting each person’s pace to elicit 40 percent of their heart rate reserve, a measure that accounts for resting and maximum heart rate, and that target was held constant across all three conditions. This ensured that any differences in blood sugar outcomes could be attributed to the robotic mode rather than to one group simply exercising harder.

Glucose was tracked with capillary blood samples taken at baseline and then every 10 minutes for a full 120 minutes after the walk began, allowing the team to construct a fine-grained picture of the post-meal glucose curve. Alongside the metabolic measurements, the researchers recorded heart rate, blood lactate concentrations, and each participant’s rating of perceived exertion, the subjective sense of how hard the effort felt. These secondary measures were critical to the study’s central question: whether robotic modes could change not just the glucose outcome but the physiological cost of achieving it.

The headline result was unambiguous. Compared with unassisted walking, both robotic modes significantly reduced total and incremental glucose exposure, mean blood glucose, peak glucose, and the magnitude of the glucose spike, all at statistical significance. The incremental area under the glucose curve, a standard summary of how much excess glucose circulates over time, fell from 6461 plus or minus 2477 mg·min/dL during unassisted walking to 4877 plus or minus 1946 under the Aqua mode and 5072 plus or minus 2339 under Boost, a reduction the authors report at P less than .001. For a population in which post-meal glucose excursions drive both daily symptom burden and long-term cardiovascular risk, a difference of that size from a single 30-minute walk is striking.

The two robotic modes, however, were not interchangeable, and the differences between them reveal an interesting physiological trade-off. The Aqua mode, which combines robotic assistance with elements of resistance, produced the strongest glycemic profile: it further reduced early glucose exposure and glucose variability compared with unassisted walking. But it came at a price. Mean heart rate during Aqua walking was 118.9 plus or minus 20.2 beats per minute, significantly higher than the 105.7 plus or minus 16.3 beats per minute recorded during unassisted walking, and peak blood lactate was also elevated, indicating greater metabolic strain.

The Boost mode told a different story. It delivered a glycemic benefit comparable to Aqua on the primary endpoints while keeping mean heart rate at 101.3 plus or minus 13.9 beats per minute, essentially indistinguishable from unassisted walking. More remarkably, participants rated the effort substantially lower: a perceived exertion score of 4.0 plus or minus 1.3 versus 5.2 plus or minus 2.3 for the unassisted condition, a difference that reached statistical significance. In other words, Boost allowed walkers to achieve better glucose control while feeling as though they were working less hard, a combination that could matter enormously for adherence in a disease where exercise prescriptions are notoriously difficult to sustain.

The mechanistic logic behind these findings rests on how hip-joint robotics reshape muscle recruitment during gait. Walking clears glucose from the bloodstream primarily through contraction-mediated uptake in the leg muscles, a pathway that operates partly independently of insulin and is therefore especially valuable in type 2 diabetes, where insulin resistance blunts the normal hormonal route. By assisting or resisting hip flexion and extension, the exoskeleton alters the pattern and intensity of muscle activation across the large muscle groups of the lower body. The Aqua mode’s higher heart rate and lactate values suggest it recruited more total muscle mass or drove greater metabolic turnover, plausibly explaining its superior effect on early glucose disposal and curve variability. Boost’s lower perceived exertion at equal heart rate suggests the device offloaded mechanical work from the walker, reducing the subjective cost of the same cardiovascular effort.

The study’s authors are careful to frame the work as an acute, proof-of-concept experiment rather than a demonstration of clinical benefit. Fourteen participants, a single post-meal session per condition, and no long-term follow-up leave open the most important questions: whether the glycemic advantage persists with repeated use, whether it translates into improvements in glycated hemoglobin or insulin sensitivity over weeks and months, and whether older adults or those with diabetic complications can tolerate the devices safely. The trial was retrospectively registered on ClinicalTrials.gov, and the funding came from Samsung Electronics, the device’s manufacturer, though the company reports no role in study design, data analysis, or the decision to publish, and the authors declare no other competing interests.

Even with those caveats, the findings point toward an intriguing convergence of rehabilitation robotics and metabolic medicine. Wearable exoskeletons have largely been developed for gait rehabilitation after stroke or spinal cord injury, and for industrial workers seeking to reduce fatigue. This study suggests a third application: precision tuning of a everyday behavior, the post-meal walk, that millions of people with diabetes are already told to perform. If larger trials confirm that robotic modes can deliver stronger glucose control at lower perceived effort, the postprandial walk could evolve from generic advice into a tunable, quantifiable intervention, with the mode selected to match an individual’s fitness, preferences, and glycemic profile. For now, the message from Seongnam is a tantalizing preview: the humble walk after dinner may have untapped potential, and a motor at the hip might be the key to unlocking it.

Subject of Research: Effects of wearable hip exoskeleton-assisted postprandial walking on glycemic responses in adults with type 2 diabetes

Article Title: Effects of wearable hip exoskeleton-assisted postprandial walking on glycemic responses in patients with type 2 diabetes: a randomized crossover study

Article References: Park, S.-B., Yang, G., & Hong, J. (2026). Effects of wearable hip exoskeleton-assisted postprandial walking on glycemic responses in patients with type 2 diabetes: a randomized crossover study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02519-0

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02519-0

Keywords: type 2 diabetes, wearable robot, hip exoskeleton, postprandial glucose, glycemic response, exercise, blood lactate, perceived exertion, crossover trial, glucose variability, heart rate reserve, Bot-Fit

The underlying clinical trial, registered as NCT05597020, enrolled 60 adults aged 55 or older who had endured insomnia symptoms for at least three months, scored 13 or higher on the Insomnia Severity Index, and reported at least three nocturnal voids per night. Participants were randomized in a one-to-one ratio to receive either daridorexant 50 mg or placebo for four weeks, then crossed over to the other treatment after a washout period of 14 to 21 days. This crossover design carries a distinct methodological advantage: each participant serves as their own control, which minimizes inter-participant variability and allows direct within-person comparisons of how the two treatments felt in everyday life.

What makes the new publication unusual is its commitment to the qualitative dimension of the patient experience. Alongside the validated questionnaires that formed the trial’s quantitative backbone, patients were asked open-ended, free-text questions at baseline and at the end of each treatment period. At screening, they described how insomnia and nocturia had impacted their daily lives before the study began. After each treatment month, they were asked how that impact had changed while taking the study medication. The replies were pooled into two groups, one containing responses from patients who had received daridorexant during either treatment period and the other containing responses from patients who had received placebo, and the analysis team remained blinded to treatment assignment until the coding was complete.

The analytic machinery behind the study was deliberately rigorous. Using MAXQDA version 2024, a qualitative data analysis platform, a trained analyst coded every response according to a structured codebook developed under a predefined Qualitative Analysis Plan. The codebook captured mentions of sleep, nocturia, and their impacts on physical, emotional, and cognitive functioning, activities of daily living, professional life, and relationships, with sub-codes recording whether patients described improvement, stability, worsening, or mixed change. Crucially, the themes emerged inductively from the data rather than being imposed by prior hypotheses, and no automated or AI-assisted coding was used. Regular meetings between the analyst, the research lead, and a scientific advisor resolved ambiguities, and all analytic decisions were logged to maintain consistency across the dataset.

The baseline picture that emerged was bleak and remarkably consistent. Of the 59 patients who replied at baseline, 68 percent described sleep problems, including difficulty falling asleep, staying asleep, and waking too early, while 37 percent described nocturia symptoms such as frequent nighttime voiding or incontinence. Two-thirds of replies referenced sleep issues and one-third referenced nocturia, suggesting that for these patients the insomnia itself was the more bothersome burden. But the damage extended far beyond the bedroom. Fully 83 percent of respondents commented on impacts on their lives, with 61 percent reporting negative effects on physical functioning, citing fatigue, tiredness, low energy, weakness, dizziness, and grogginess, and 52.5 percent reporting emotional tolls including frustration, irritability, stress, and nervousness. One in five described impaired cognition, and work and social life suffered as well.

After four weeks on treatment, the contrast between daridorexant and placebo was striking. Among patients taking daridorexant, 87 percent reported improvement in their sleep, compared with just 50 percent on placebo, a difference the researchers found highly significant with a p value of 0.0011. Only 10 percent of daridorexant patients said their sleep problems were unchanged, versus 40 percent of placebo patients. The nocturia findings were, if anything, more dramatic: 79 percent of patients on daridorexant reported improvement in their nighttime voiding, compared with 32 percent on placebo, a highly significant difference with a p value of 0.0013. These patient-perceived improvements align closely with the trial’s quantitative results, which showed that daridorexant increased subjective total sleep time by roughly 21 minutes and reduced nocturnal voids by an average of 1.5 episodes per night.

The benefits rippled outward into daily functioning. Improvements in quality-of-life impacts were reported by 73.7 percent of daridorexant patients who commented on impacts, compared with 46.7 percent of placebo patients. Physical functioning showed the largest gains, with 52.6 percent of daridorexant patients reporting improvement versus 26.7 percent on placebo. Cognitive functioning, activities of daily living, and emotional functioning also improved more frequently under daridorexant, with placebo patients showing no reported cognitive improvements at all. Patients described feeling less fatigued, more able to concentrate, and better equipped to manage ordinary routines that fragmented sleep had made exhausting.

Why would a sleep drug ease the urge to urinate at night? The authors offer two complementary hypotheses. The first is mechanical: by lengthening sleep duration and shortening long awakenings, daridorexant simply gives patients fewer opportunities to notice a full bladder, an explanation supported by earlier work showing that behavioral treatment of insomnia alone reduced self-reported nocturnal voids in older adults. The second is neurobiological and arguably more intriguing. The orexin system, best known for stabilizing wakefulness, also appears to influence micturition. Animal studies have shown that orexin-A activates the micturition reflex, and that blocking orexin 2 receptors restores abnormal bladder markers in models of overactive bladder. In humans, orexin antagonists may increase bladder capacity by prolonging the interval between bladder contractions. Consistent with this, orexin agonists given to people with narcolepsy have produced increased urinary urgency and frequency as expected on-target effects, the mirror image of what antagonists appear to do.

The study’s authors argue that these findings fill a genuine gap in sleep medicine. A systematic review of qualitative insomnia research identified only 22 published studies, many of which actually relied on quantitative methods, and concluded that well-conducted qualitative work in the field remains scarce compared with areas such as depression. Free-text responses complement structured patient-reported outcome measures by adding contextual depth, capturing experiences such as non-restorative sleep and mood disturbance that objective measures may miss. The longitudinal design of the survey, with baseline responses collected before treatment, also avoids the recall bias inherent in asking patients at study exit to reconstruct how they felt months earlier. And because patients were blinded to treatment and the analysts were blinded too, expectancy effects were constrained as far as the design allows.

Limitations remain, and the authors are candid about them. Responses summarized an entire month retrospectively, inviting recall bias, and the level of detail varied considerably across patients. A few replies were missing or uninterpretable, and subjective free-text data can still be shaped by placebo and expectancy effects even in a blinded crossover. Coding inevitably involves some interpretive judgment, mitigated here by a predefined analysis plan, blinded coding, and documented quality checks. The study also relied on patient history rather than polysomnography to exclude other sleep disorders. Even so, the message is compelling: patients with moderate to severe insomnia and clinically meaningful nocturia reported broad damage to their physical, emotional, and cognitive lives, and daridorexant 50 mg consistently elicited more positive patient-reported change than placebo across sleep, voiding, and daily functioning. As clinical trials increasingly seek to center the patient’s voice, this study offers a template for letting patients describe, in their own words, what treatment actually feels like.

Subject of Research: Qualitative patient-reported outcomes of daridorexant treatment in adults with chronic insomnia and comorbid nocturia

Article Title: Capturing the Patient Voice: Qualitative Assessment of Daridorexant’s Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial

Article References: Arnaldi, D., Bliwise, D. L., Alpan, D., Koochaki, P., Meinel, M., Olivieri, A., Rowles, R., Satapathy, A., & Lederer, K. (2026). Capturing the Patient Voice: Qualitative Assessment of Daridorexant’s Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial. Advances in Therapy. https://doi.org/10.1007/s12325-026-03803-0

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03803-0

Keywords: daridorexant, insomnia, nocturia, dual orexin receptor antagonist, patient-reported outcomes, qualitative research, crossover trial, sleep medicine, quality of life, orexin system, placebo-controlled trial, daytime functioning